About Us

Driving DUB drug discovery and development

As pioneers in the rapidly emerging deubiquitinase (DUB) space, Ubiquigent™ is uniquely positioned to drive forward the discovery and development of novel DUB inhibitors, DUB-targeting Proteolysis Targeting Chimeras (PROTACs) and DUB-targeting Chimeras (DUBTACs) as powerful new therapeutics for areas of high unmet need.

Since being established in 2009, Ubiquigent has cultivated an unrivalled track record and comprehensive range of specialist products and services focused on the exploitation of DUBs and the ubiquitin-proteasome system (UPS). As such, we are the partner chosen by many leading industry and academic organisations for their DUB-focused drug discovery and development programmes spanning the fields of protein degradation, stabilisation, and signalling.

Alongside the delivery of our products and services, we are developing an internal collection of compounds that can accessed through partnerships and out-licensing agreements by our clients as new starting points for their discovery programmes.

Ubiquigent is a revenue and IP-generating company that benefits from the support of its investors, including IP Group PLC and Scottish Enterprise. We’re located in Dundee, Scotland, where we sit at the centre of a growing hub of highly relevant scientific expertise and capabilities.

Mark Treherne PhD

Mark Treherne PhD

Chairman of the Board

Read Bio

Jason Mundin MBA

Jason Mundin MBA

Chief Executive Officer, Board Member

Read Bio

Sheelagh Frame PhD

Sheelagh Frame PhD

Chief Scientific Officer, Board Member

Read Bio

Hozefa Amijee PhD

Hozefa Amijee PhD

Head of Business Development

Read Bio

Rishi Shah PhD

Rishi Shah PhD

Head of Chemistry

Read Bio

Laurence Ede

Laurence Ede

Board Member

Read Bio

Ian Ratcliffe

Ian Ratcliffe

Board Member

Read Bio